NEW YORK STOCK EXCHANGE, INC. · ADCT
-3.74% · -$0.0400 · Vol 1.7M
Market closed · last close 4:00 PM ET · price as of 19:58:36 ET
ADC Therapeutics SA

ADC Therapeutics SA

Biotechnology
$1.03

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is ADCT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About ADC Therapeutics SA
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
193
Country
CH

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.07
Day high
$1.10
Day low
$1.00
Previous close
$1.07
52W high
$1.10
-6.36% from high
52W low
$0.9963
32% of range
Market cap
$136.1M
EPS
$-1.3700
Shares out
127.2M
Volume
1.7M
VWAP
$1.04
Price history computed in-house
1W
-5.50%
SMA 50 $1.07 · below
SMA 200 $1.07 · below
52W position 32%
Veridion warehouse edge

Warehouse intelligence for ADCT.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ADCT insider activity

ADC Therapeutics SA

Score
Coverage building
Pressure
Net buying
Filings
30
Buys / sells
7 / 23
Net value
$15.4M
Insiders
13
Named filers
MV
Monges Viviane
Insider
Leadership
HP
Hug Peter
Insider
Leadership
AR
Azelby Robert
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net buying: $15.4M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-032026-06-03Monges VivianeInsidersell$3.082,596186,447$8KSEC Form 4
2026-06-032026-06-03Hug PeterInsidersell$3.082,156263,344$7KSEC Form 4
2026-06-032026-06-03Azelby RobertInsidersell$3.0812,600112,805$39KSEC Form 4
2026-06-032026-06-03BIZZARI JEAN-PIERREInsidersell$3.0812,600139,302$39KSEC Form 4
2026-06-032026-06-03Sandor VictorInsidersell$3.0812,600140,686$39KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 25 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ADCT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ADCT in this window.
Lobbying spend

ADCT lobbying filings, year to date.

Registered lobbying filings matched to ADC Therapeutics SA.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ADCT in this window.
Latest news · ADCT
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ADCT.
Options
Sovereign unlock shows live options positioning for ADCT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.